Drug Profile
CER 002
Alternative Names: CER-002; NC-2400Latest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator Nippon Chemiphar
- Developer ABIONYX Pharma
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atherosclerosis; Dyslipidaemias
Most Recent Events
- 10 Apr 2024 CER 002 is still in phase I trials for Dyslipidaemias and Atherosclerosis in USA (ABIONYX pipeline, April 2024)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Dyslipidaemias in USA (PO)
- 15 Sep 2015 CER 002 is still in phase I clinical development for Dyslipidaemias in USA